| Literature DB >> 21907711 |
George T Lountos1, Andrew G Jobson, Joseph E Tropea, Christopher R Self, Guangtao Zhang, Yves Pommier, Robert H Shoemaker, David S Waugh.
Abstract
The serine/threonine checkpoint kinase 2 (Chk2) is an attractive molecular target for the development of small molecule inhibitors to treat cancer. Here, we report the rational design of Chk2 inhibitors that target the gatekeeper-dependent hydrophobic pocket located behind the adenine-binding region of the ATP-binding site. These compounds exhibit IC(50) values in the low nanomolar range and are highly selective for Chk2 over Chk1. X-ray crystallography was used to determine the structures of the inhibitors in complex with the catalytic kinase domain of Chk2 to verify their modes of binding. Published by Elsevier B.V.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21907711 PMCID: PMC3195894 DOI: 10.1016/j.febslet.2011.08.050
Source DB: PubMed Journal: FEBS Lett ISSN: 0014-5793 Impact factor: 4.124